RxDoctor Payments Data

Traci Boyd, APRN

Family · Grayson, KYNPI 1245594811

Payments from drug & device makers

$3,493in general payments, 2019–2025

Across 210 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$755
  • GSK$389
  • Lilly USA, LLC$327
  • Grifols USA, LLC$230
  • Biohaven Pharmaceuticals, Inc.$188
  • Novo Nordisk$154
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$3,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,493 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$22,946
Medicare patients
144
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$75,055
TrulicityDulaglutide59$62,654
MounjaroTirzepatide47$50,536
EliquisApixaban64$47,534
LinzessLinaclotide35$30,699
JanuviaSitagliptin Phosphate25$30,456
JardianceEmpagliflozin20$18,097
EntrestoSacubitril/Valsartan25$17,824
XareltoRivaroxaban14$14,873
Breo ElliptaFluticasone/Vilanterol18$11,891
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,097
SymbicortBudesonide/Formoterol Fumarate15$4,788
Ondansetron Hcl14$4,592
Albuterol Sulfate HfaAlbuterol Sulfate119$4,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$327$113,190106 claims
Novo NordiskOzempic$154$75,05580 claims
PfizerEliquis$112$47,53464 claims
AbbVieLinzess$755$30,69935 claims
MerckJanuvia$145$30,45625 claims
GSKBreo Ellipta, Trelegy Ellipta$389$22,98831 claims
Boehringer IngelheimJardiance$17$18,09720 claims
AstraZenecaSymbicort$13$4,78815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Grayson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →